Letter by Puri et al Regarding Article, “Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control” | Zendy

Raman Puri | Zendy; Sonam Puri | Zendy; Anil Rajani | Zendy

Open Access

Letter by Puri et al Regarding Article, “Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control”

Author(s) -

Raman Puri,

Sonam Puri,

Anil Rajani

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.026822

Subject(s) - medicine , new delhi , alirocumab , pathology , cholesterol , apolipoprotein a1 , metropolitan area , apolipoprotein b

We read with great interest the article by Ray et al1 about major adverse cardiovascular events outcomes in patients with low-density lipoprotein cholesterol (LDL-C) <50 mg/dL. It has been a well-known fact that South Asians have an atherogenic dyslipidemia [high triglycerides and low high-density lipoprotein cholesterol (HDL-C)] at baseline,2 are at higher cardiovascular risk, and develop coronary artery disease ≈1 decade earlier than whites. Hence, guidelines by the Lipid Association of India have laid great …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research